NovaBay Pharmaceuticals (NBY) Competitors $0.60 +0.01 (+2.51%) As of 08/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock NBY vs. NXTC, ALVR, CYCC, LPTX, CARM, TXMD, NERV, PRPH, IMNN, and ERNAShould you be buying NovaBay Pharmaceuticals stock or one of its competitors? The main competitors of NovaBay Pharmaceuticals include NextCure (NXTC), AlloVir (ALVR), Cyclacel Pharmaceuticals (CYCC), Leap Therapeutics (LPTX), Carisma Therapeutics (CARM), TherapeuticsMD (TXMD), Minerva Neurosciences (NERV), ProPhase Labs (PRPH), Imunon (IMNN), and Ernexa Therapeutics (ERNA). These companies are all part of the "pharmaceutical products" industry. NovaBay Pharmaceuticals vs. Its Competitors NextCure AlloVir Cyclacel Pharmaceuticals Leap Therapeutics Carisma Therapeutics TherapeuticsMD Minerva Neurosciences ProPhase Labs Imunon Ernexa Therapeutics NextCure (NASDAQ:NXTC) and NovaBay Pharmaceuticals (NYSE:NBY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability. Do insiders & institutionals believe in NXTC or NBY? 42.7% of NextCure shares are held by institutional investors. Comparatively, 23.3% of NovaBay Pharmaceuticals shares are held by institutional investors. 17.9% of NextCure shares are held by insiders. Comparatively, 0.1% of NovaBay Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more risk and volatility, NXTC or NBY? NextCure has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, NovaBay Pharmaceuticals has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Do analysts rate NXTC or NBY? NextCure presently has a consensus target price of $25.50, suggesting a potential upside of 395.15%. NovaBay Pharmaceuticals has a consensus target price of $0.85, suggesting a potential upside of 40.54%. Given NextCure's higher possible upside, equities research analysts plainly believe NextCure is more favorable than NovaBay Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NextCure 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67NovaBay Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor NXTC or NBY? In the previous week, NextCure had 2 more articles in the media than NovaBay Pharmaceuticals. MarketBeat recorded 2 mentions for NextCure and 0 mentions for NovaBay Pharmaceuticals. NovaBay Pharmaceuticals' average media sentiment score of 0.00 beat NextCure's score of -0.25 indicating that NovaBay Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment NextCure Neutral NovaBay Pharmaceuticals Neutral Which has preferable valuation and earnings, NXTC or NBY? NovaBay Pharmaceuticals has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than NovaBay Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNextCureN/AN/A-$55.65M-$25.82-0.20NovaBay Pharmaceuticals$9.78M0.36-$9.64M-$53.72-0.01 Is NXTC or NBY more profitable? NextCure has a net margin of 0.00% compared to NovaBay Pharmaceuticals' net margin of -102.72%. NextCure's return on equity of -106.62% beat NovaBay Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NextCureN/A -106.62% -85.20% NovaBay Pharmaceuticals -102.72%-7,293.78%-158.41% SummaryNextCure beats NovaBay Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get NovaBay Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBY vs. The Competition Export to ExcelMetricNovaBay PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$3.43M$791.77M$5.61B$21.04BDividend YieldN/A4.84%4.61%3.57%P/E Ratio-0.011.1830.2728.08Price / Sales0.3626.06469.9557.05Price / CashN/A19.5638.2123.95Price / Book0.146.588.845.26Net Income-$9.64M-$4.98M$3.25B$994.11M7 Day Performance2.08%1.90%3.71%2.09%1 Month Performance-9.73%0.50%5.85%2.35%1 Year Performance22.90%16.35%30.25%13.36% NovaBay Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBYNovaBay Pharmaceuticals1.692 of 5 stars$0.60+2.5%$0.85+40.5%+30.3%$3.43M$9.78M-0.0130Gap DownNXTCNextCure4.2086 of 5 stars$5.08+0.7%$25.50+402.4%-72.1%$13.70MN/A-0.2490Short Interest ↑ALVRAlloVirN/A$2.69+0.4%N/A-86.6%$13.57MN/A-0.13110High Trading VolumeCYCCCyclacel Pharmaceuticals1.2748 of 5 stars$8.49-13.5%N/A-97.4%$13.46M$14K-0.0114News CoveragePositive NewsEarnings ReportGap DownLPTXLeap Therapeutics2.4145 of 5 stars$0.32-10.0%$3.38+944.9%-90.1%$13.39MN/A-0.1940News CoverageEarnings ReportShort Interest ↓Gap DownHigh Trading VolumeCARMCarisma Therapeutics3.1584 of 5 stars$0.31+1.0%$1.93+519.0%-71.8%$13.00M$19.63M-0.2020Short Interest ↓TXMDTherapeuticsMD0.499 of 5 stars$1.11+0.9%N/A-29.0%$12.84M$1.76M0.00420Earnings ReportNERVMinerva Neurosciences4.1209 of 5 stars$1.83-3.3%$5.00+173.2%-35.9%$12.79MN/A2.239News CoverageEarnings ReportGap DownPRPHProPhase Labs1.1052 of 5 stars$0.30-2.0%N/A-86.7%$12.63M$5.85M-0.24130Earnings ReportGap DownIMNNImunon1.7166 of 5 stars$8.87-3.6%$232.50+2,521.2%-54.0%$12.60MN/A-0.4330Short Interest ↑ERNAErnexa Therapeutics0.6482 of 5 stars$1.68+7.4%N/A-93.8%$12.34M$535K-0.2010Earnings ReportShort Interest ↑ Related Companies and Tools Related Companies NXTC Alternatives ALVR Alternatives CYCC Alternatives LPTX Alternatives CARM Alternatives TXMD Alternatives NERV Alternatives PRPH Alternatives IMNN Alternatives ERNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NBY) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovaBay Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NovaBay Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access